GEA invests EUR 80 million in a pharmaceutical technology center for freeze-drying systems in Germany
First product chambers in the “Factory of the Future”
Advertisement
GEA is investing EUR 80 million in the construction of a pharmaceutical technology center for freeze-drying systems in Elsdorf (North Rhine-Westphalia). Partial approval was granted by the authorities in July 2025. With the new location, GEA is responding to the growing global demand for freeze-drying systems while creating capacity for further growth and technological innovation. The relocation of the previous operations in Hürth to Elsdorf has now begun. Shortly after the partial handover, the first product chambers, central components for the production of freeze dryers in which the actual drying process takes place, were delivered. The installation of the first freeze dryers at the new location represents an important milestone in the construction of GEA's new pharmaceutical technology center.
Covering an area of more than 40,000 square meters, the new competence and production center will primarily be used for the construction of freeze drying systems, which are used worldwide for the manufacture of injectable drugs such as vaccines. The complete relocation of the production, storage, and laboratory areas as well as the administrative functions will take place in the fourth quarter of 2025.
Strategic investment in innovation and sustainability
The “Factory of the Future” in Elsdorf stands for future-proof production processes, consistent digitalization, and sustainable construction: The photovoltaic system supplies environmentally friendly electricity, waste heat is recycled, and green roof areas promote a pleasant working environment and a focus on biodiversity. An intelligent warehouse management system and digital workflows ensure increased efficiency and transparency in operations.
Further assembly in “early access” mode
The partial approval gives the GEA team access to the first assembly areas while construction work continues elsewhere. This means that the assembly of complex systems can begin at an early stage, avoiding time-consuming relocation of these large components at a later date. The gradual commissioning process guarantees that the project will be completed on time and within budget.
Background information: Facts about the new pharmaceutical technology center
- New building enables growth and innovation in the strategically important pharmaceutical sector
- GEA's second factory of the future is being built in Elsdorf on a site covering more than 40,000 m²
- The construction of the new site in Elsdorf complies with the highest sustainability standards (e.g., own energy generation, CO₂ neutrality) and includes new, innovative digital solutions for the entire value chain.
- All 250 permanent employees will move to the new location
Other news from the department manufacturing
Most read news
More news from our other portals
Last viewed contents
PL BioScience Announces Major Site Expansion - New 1,200 m² facility in Aachen expands headquarters to support company growth and scale Human Platelet Lysate production
Stora Enso’s billion-euro investment in renewable packaging - Europe's most modern consumer board production line inaugurated in Finland
NextPharma announces the appointment of Ajeeth Enjeti as CEO to succeed Peter Burema
Dr. Roland Durner becomes new CEO of Bioengineering AG
GDCh Award for Biocatalysis for Sebastian Gergel
Michael Grosse to succeed Joachim Kreuzburg as Chief Executive Officer of Sartorius AG - Grosse to take over as Group CEO on July 1, 2025
WACKER BIOSOLUTIONS under New Leadership - Susanne Leonhartsberger will leave the company at her own request at the end of 2024.
DMC Biotechnologies announces Dr. Jim Flatt as CEO - DMC seeking to transform how the world makes chemicals
Merck: New CEOs for Life Science and Healthcare business sectors and New Chief People Officer - Appointment of three internal senior executives ensures strategic continuity with a new era of leadership
Joachim Kreuzburg, Former CEO of Sartorius, Joins Cube Biotech’s Board of Directors
Prize for bioconversion of renewable raw materials - Daniel Eggerichs has bacteria produce plastic precursors from paper production waste
